Five out of the 45 companies that set out to evade the patent of Boryung Pharmaceutical's antihypertensive combination drug ‘Dukarb Tab. (fimasartan+amlodipine)’ decided to give up challenging the patent.

The industry has pointed to the fierce competition in the two-drug fixed-dose combination market as one of the causes for the companies’ decision to give up their patent challenge.

According to industry sources on the 6th, PharmGen Science voluntarily withdrew the trial to confirm the passive scope of patent rights that it had recently filed for the Dukarb composition patent.

If the companies succeed in avoiding the composition patent for Dukarb which is set to